An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYN
A phase 2 trial of Intismeran autogene, Pembrolizumab in melanoma, run by ModernaTX, Inc., active and no longer recruiting.
Overview
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) is a phase 2 interventional study registered as NCT03897881 by ModernaTX, Inc., with 267 participants enrolled, started 2019-07-18 and due to reach its primary completion in 2032-11-21. Interventions recorded: mRNA-4157, Pembrolizumab. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Shares Intismeran autogene, Melanoma, Pembrolizumab.
- TrialA Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
Shares Intismeran autogene, Pembrolizumab.
- TrialA Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (
Shares Intismeran autogene, Pembrolizumab.
- TrialA Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Shares Intismeran autogene, Pembrolizumab.
- IdeaPersonalised cancer vaccines at commodity cost through fully automated manufacturing
Shares Moderna, Intismeran autogene, Melanoma.
- TrialA Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Shares Intismeran autogene, Pembrolizumab.
- IdeaPersonalised vaccines given only when the blood test turns positive
Shares Moderna, Intismeran autogene, Melanoma.
- TrialA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Shares Intismeran autogene, Pembrolizumab.